4-[3-(piperidin-4-yl)-1H-pyrazol-5-yl]pyridine dihydrochloride | 2136571-30-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-[3-(piperidin-4-yl)-1H-pyrazol-5-yl]pyridine dihydrochloride
• 英文别名: 4-(5-piperidin-4-yl-1H-pyrazol-3-yl)pyridine;dihydrochloride
• CAS: 2136571-30-5
• 化学式: C13H18Cl2N4
• mdl: MFCD22196616
• 分子量: 301.21
• InChiKey: ASYCTHXAPLLLSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.86
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  53.6
• 氢给体数：
  4
• 氢受体数：
  3

文献信息

• METHOD OF INHIBITING HIGH FAT DIET-RELATED CONDITIONS
  申请人：South Australian Health and Medical Research Institute Limited

  公开号：EP3436152A1

  公开（公告）日：2019-02-06
• [EN] METHOD OF INHIBITING HIGH FAT DIET-RELATED CONDITIONS<br/>[FR] PROCÉDÉ D'INHIBITION D'ÉTATS ASSOCIÉS À UN RÉGIME RICHE EN MATIÈRES GRASSES
  申请人：SOUTH AUSTRALIAN HEALTH AND MEDICAL RES INST LTD

  公开号：WO2017165908A1

  公开（公告）日：2017-10-05

  A method of treating a pre-diabetic subject is disclosed wherein the subject is characterised by having a fasting plasma glucose level from 5.5 mmol/1 to 6.9 mmol/1. The method comprises administering to the subject a therapeutically effective amount of at least one mitogen-activated protein kinase- interacting kinase (MNK) inhibitor, wherein said MNK inhibitor reduces the biological activity of MNK1 and/or MNK2. The method may prevent and/or delay progression of pre-diabetes to type 2 diabetes. The method may also prevent progression of pre-diabetes at the impaired fasting glucose (IFG) stage to the impaired glucose tolerance (IGT) stage.